REG - Destiny Pharma PLC - Result of General Meeting and Total Voting Rights

Destiny PharmaAnnouncement

16/03/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230316:nRSP2671Ta&default-theme=true

RNS Number : 2671T  Destiny Pharma PLC  16 March 2023

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED
HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES,
AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

Destiny Pharma plc

Result of General Meeting

and

Total Voting Rights

Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), a clinical
stage innovative biotechnology company focused on the development of novel
medicines that can prevent life-threatening infections, announces that, at the
General Meeting held earlier today, all resolutions proposed were duly passed
by shareholders on a poll.

 

Accordingly, the Company has raised total gross proceeds
of approximately £7.34 million from the Fundraising and has allotted a
total of 20,961,956 New Shares. Admission of the Second Placing Shares, the
Subscription Shares and the Open Offer Shares, is expected to occur on 17
March 2023.

Following Admission on 17 March 2023, the Company's issued ordinary share
capital will comprise 94,459,061 Ordinary Shares, none of which are held in
treasury. The above figure of 94,459,061 may be used by Shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
voting rights of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

A summary of the votes received for the General Meeting will be made available
on the Company's website at www.destinypharma.com
(file:///C%3A/Users/MahweenS/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/TU3V12QJ/www.destinypharma.com)
.

Unless otherwise defined herein, capitalised terms used in this announcement
shall have the same meanings as defined in the announcement of the Fundraising
made by the Company on 24 February 2023.

 

Enquiries:

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         Neil Clark
 2.      Reason for the Notification
 a)      Position/status                                              Chief Executive Officer
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Destiny Pharma plc
 b)      LEI                                                          213800O9WH9Z38EHAC95
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each ("Ordinary Shares")
         Identification code                                          GB00BDHSP575
 b)      Nature of the transaction                                    Purchase of Ordinary Shares

 c)      Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                      35p           28,571
 d)      Aggregated information:

         Aggregated volume                                            See 4c) above

         Price
 e)      Date of the transaction                                      16 March 2023
 f)      Place of the transaction                                     London Stock Exchange, AIM Market

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above

 

e)

Date of the transaction

16 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         Shaun Claydon
 2.      Reason for the Notification
 a)      Position/status                                              Chief Financial Officer
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Destiny Pharma plc
 b)      LEI                                                          213800O9WH9Z38EHAC95
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each ("Ordinary Shares")
         Identification code                                          GB00BDHSP575
 b)      Nature of the transaction                                    Purchase of Ordinary Shares

 c)      Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                      35p           14,286
 d)      Aggregated information:

         Aggregated volume                                            See 4c) above

         Price
 e)      Date of the transaction                                      16 March 2023
 f)      Place of the transaction                                     London Stock Exchange, AIM Market

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above

 

e)

Date of the transaction

16 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         Nick Rodgers
 2.      Reason for the Notification
 a)      Position/status                                              Chairman
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Destiny Pharma plc
 b)      LEI                                                          213800O9WH9Z38EHAC95
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each ("Ordinary Shares")
         Identification code                                          GB00BDHSP575
 b)      Nature of the transaction                                    Purchase of Ordinary Shares

 c)      Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                      35p           28,571
 d)      Aggregated information:

         Aggregated volume                                            See 4c) above

         Price
 e)      Date of the transaction                                      16 March 2023
 f)      Place of the transaction                                     London Stock Exchange, AIM Market

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above

 

e)

Date of the transaction

16 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMZZGMFKVRGFZM